Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | ADK | P55263 | 13/20 | 0.46 |
| ▸ | PNP | P00491 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15670883 | 0.78 | LMNA (0.56) | ADORA3TSHRLMNAMAPTPMP22 | |
| SCHEMBL3851144 | 0.78 | LMNA (0.56) | ADORA3TSHRLMNAMAPTPMP22 | |
| SCHEMBL188236 | 0.72 | NT5E (0.41) | SMN1; SMN2 | |
| SCHEMBL4879682 | 0.70 | LMNA (0.67) | TSHRLMNAMAPT | |
| SCHEMBL10015791 | 0.70 | LMNA (0.67) | TSHRLMNAMAPT | |
| SCHEMBL399323 | 0.70 | LMNA (0.67) | TSHRLMNAMAPT | |
| SCHEMBL399324 | 0.70 | LMNA (0.67) | TSHRLMNAMAPT | |
| SCHEMBL7170446 | 0.69 | ADORA3 (0.56) | ADORA3ADK | |
| 5'-Deoxyadenosine SCHEMBL542617 | 0.68 | AHCY (0.69) | ADORA3SMN1; SMN2 | |
| 5'-Deoxyadenosine SCHEMBL3459552 | 0.68 | AHCY (0.69) | ADORA3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS INC (US) | 2017-08-03 | — | — | US | disclosed |
| EP-3132796-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | Pericor Therapeutics, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9539274-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-8993527-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2594273-A1 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | Pericor Therapeutics, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20080175891-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20060293273-A1 | Methods, Compositions, and Formulations for Preventing or Reducing Adverse Effects in a Patient | PERICOR THERAPEUTICS, INC. | 2006-12-28 | — | — | US | disclosed |
| EP-0495091-B1 | AICA RIBOSIDE ANALOGS | METABASIS THERAPEUTICS INC (US) | 1999-11-24 | — | — | EP | disclosed |
| US-5777100-A | INCREASING LEVELS OF ADENOSINE, CARDIOVASCULAR, ISCHEMIA | GENSIA INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1992002214-A1 | AICA RIBOSIDE ANALOGS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002213-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | ADORA3 2372/4885ADK 3140/4885PNP 1418/4885 |
| US-20060293273-A1 | Methods, Compositions, and Formulations for Preventing or Reducing Adverse Effects in a Patient | TNNC1, ASAH2, PGF | ADORA3 2372/4885ADK 3140/4885PNP 1418/4885 |
| US-20080175891-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | NNT, PGF, GART | ADORA3 127/4885ADK 202/4885PNP 162/4885 |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | ADORA3 2372/4885ADK 3140/4885PNP 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.